Skip to main content

BOK Antibody [PerCP]

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-41045PCP

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Validated:

Human

Predicted:

Mouse (100%), Rat (100%). Backed by our 100% Guarantee.

Applications

ELISA, Immunohistochemistry, Immunohistochemistry-Paraffin

Label

PerCP (Excitation = 490 nm, Emission = 675 nm)

Antibody Source

Polyclonal Rabbit IgG

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

Antibody was raised against a 16 amino acid synthetic peptide near the amino terminus of human BOK. The immunogen is located within the first 50 amino acids of BOK. Amino Acid Squence: DAFDRSPTDKELVAQA

Reactivity Notes

Immunogen displays the following percentage of sequence identity for non-tested species: Chicken (81%).

Specificity

At least three isoforms of BOK are known to exist; this antibody will not detect the smallest isoform. BOK antibody is predicted to not cross-react with other Bcl-2 protein family members

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Applications for BOK Antibody [PerCP]

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry-Paraffin

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Peptide affinity purified

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: BOK

Apoptosis or programmed cell death is a physiological cellular process characterized by cell shrinkage, membrane blebbing, DNA fragmentation, and release of Cytochrome C from the mitochondria. It is utilized by the organism to get rid of unwanted cells, which is critical for normal development and homeostasis of an organism. Disregulation of normal apoptosis process have been implicated in a variety of diseases, including cancer, autoimmune diseases, viral infections, etc. Programmed cell death occurs through complex cascades of cell signaling in which Bcl-2 family members, among others, play an important role.The Bcl-2 family of proteins regulate apoptosis as well as execute death signals at the mitochondrion. Members of this family include both pro- and anti-apoptotic proteins that hare homology sequences called Bcl-2 Homology domains (BH1-4) which mediate dimmer formation. The BH3 proteins, such as BID, NOXA, PUMA, BIK, BIM and BAD are all pro-apoptotic and share sequence homology within the amphipathic alpha-helical BH3 region, which is required for their apoptotic function. They may trigger release of death-inducing molecules such as Cytochrome C, Smac, and endonuclease G. Anti-apoptotic family members, including Bcl-2 and Bcl-XL, play inhibitory roles. Bcl-2 family proteins may form homodimers or heterodimers between pro- and anti-apoptotic members, the ratios of which determine the cell fate.

Long Name

Bcl-2-related Ovarian Killer

Alternate Names

bcl2-L-9, BCL2L9bcl-2-related ovarian killer protein, Bcl-2-like protein 9, BCL2-related ovarian killer, BOKL, hBOK, MGC4631

Gene Symbol

BOK

Additional BOK Products

Product Documents for BOK Antibody [PerCP]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for BOK Antibody [PerCP]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...